Voyager Therapeutics, Inc. (VYGR) News
Filter VYGR News Items
VYGR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VYGR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VYGR News From Around the Web
Below are the latest news stories about VOYAGER THERAPEUTICS INC that investors may wish to consider to help them evaluate VYGR as an investment opportunity.
Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Voyager Therapeutics, Inc. (NASDAQ:VYGR) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […] |
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025. |
Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Key Insights Institutions' substantial holdings in Voyager Therapeutics implies that they have significant influence... |
Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 152.5% in Voyager Therapeutics (VYGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Wedbush upgrades Voyager to Outperform on pipeline progressWedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for Alzheimer’s disease program and the AAV-mediated siRNA program for amyotrophic lateral sclerosis caused by mutations in the SOD1 gene into its valuation. Voyager’s clinical and preclinical data that became available recently should allow for improved visibility into potential clinical outcomes for both p |
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nominated leveraging Voyager’s IV-delivered, CNS-penetrant TRACER capsids - LEXINGTON, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has selected a lead development candidat |
Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?It is hard to get excited after looking at Voyager Therapeutics' (NASDAQ:VYGR) recent performance, when its stock has... |
Q3 2024 Voyager Therapeutics Inc Earnings CallQ3 2024 Voyager Therapeutics Inc Earnings Call |
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...Voyager Therapeutics Inc (VYGR) reports a robust financial runway and advances in Alzheimer's research, despite challenges in clinical trials. |
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of 64.44% and 95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |